Advertisement

Pharmacokinetics and Bioequivalence Evaluation of a New Oxycodone Tamper-Resistant Tablet Administered with an Opioid Antagonist in Patients with Chronic Pain

  • Zhu Luo
  • Jia Miao
  • Shiqing Shu
  • Ying Wang
  • Xiaohong Zhu
  • Chao Hu
  • Yali ShenEmail author
Original Research Article
  • 23 Downloads

Abstract

Background and Objectives

Oxycodone tamper resistant (OTR) is a new extended-release abuse-deterrent formulation providing improvements in the tamper resistant characteristics. This study aimed to investigate the pharmacokinetic properties of the new OTR tablets and evaluate the bioequivalence of oxycodone from OTR and the original extended release (ER) formulation tablets administered with an opioid antagonist in patients with chronic pain.

Methods

In this open-label, randomized, cross-over study, the enrolled patients were randomised to receive a single dose of 40 mg OTR or 40 mg OXYCONTIN® (OXY) tablet administered with naltrexone blockade under fasting conditions. Serial blood samples for pharmacokinetic analysis were collected. Plasma oxycodone was quantified by a high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS) method. Tolerability was evaluated by monitoring adverse events, physical examinations, 12-lead ECG and laboratory tests.

Results

A total of 38 patients were enrolled and 33 subjects completed the study. After a single dose of 40 mg tablets, pharmacokinetic results of the new OTR tablet were found to be similar to those of original extended-release oxycodone tablet. OTR 40 mg was bioequivalent to OXY 40 mg and was well tolerated in patients with chronic pain.

Conclusions

The new OTR formulation could provide a new choice in the treatment of chronic pain and reduce the potential for oxycodone abuse.

Chictr.org identifier: ChiCTR1800017253.

Notes

Compliance with Ethical Standards

Funding

The study was sponsored and funded by Mundipharma (China) Pharmaceutical Co. Ltd. (Beijing, People’s Republic of China).

Conflict of interest

The authors have declared that no financial relationships with any organizations that might have an interest in the submitted work; no other relationships or activities that could influence the submitted work.

Ethical approval

The study protocol was approved by the Independent Ethics Committee of West China Hospital, Sichuan University (Chengdu, China). All procedures in this study were carried out in accordance with the Helsinki declaration.

Informed consent

Written informed consent was obtained from each subject before screening procedures.

Supplementary material

40261_2019_870_MOESM1_ESM.pdf (3.3 mb)
Supplementary material 1 (PDF 3329 kb)

References

  1. 1.
    Riley J, Eisenberg E, Muller-Schwefe G, et al. Oxycodone: a review of its use in the management of pain. Curr Med Res Opin. 2008;24(1):175–92.CrossRefGoogle Scholar
  2. 2.
    Lugo RA, Kern SE. The pharmacokinetics of oxycodone. J Pain Palliat Care Pharmacother. 2005;18(4):17–30.CrossRefGoogle Scholar
  3. 3.
    The Medical Letter Inc. Abuse-deterrent opioids. Med Lett Drugs Ther. 2017;59(1522):95–6.Google Scholar
  4. 4.
    Pergolizzi JV Jr, Raffa RB, Taylor R Jr, et al. Abuse-deterrent opioids: an update on current approaches and considerations. Curr Med Res Opin. 2018;34(4):711–23.CrossRefGoogle Scholar
  5. 5.
    Keast SL, Owora A, Nesser N, et al. Evaluation of abuse-deterrent or tamper-resistant opioid formulations on overall health care expenditures in a state medicaid program. J Manag Care Spec Pharm. 2016;22(4):347–56.PubMedGoogle Scholar
  6. 6.
    Guy GP Jr, Zhang K, Bohm MK, et al. Vital signs: changes in opioid prescribing in the United States, 2006–2015. MMWR Morb Mortal Wkly Rep. 2017;66(26):697–704.CrossRefGoogle Scholar
  7. 7.
    Nguyen V, Raffa RB, Taylor R, et al. The role of abuse-deterrent formulations in countering opioid misuse and abuse. J Clin Pharm Ther. 2015;40(6):629–34.CrossRefGoogle Scholar
  8. 8.
    Investigator’s Brochure of Oxycodone Tamper Resistant (Reformulated Oxycontin), Purdue Pharma, released date Jun/2016, edition number 16.1.Google Scholar
  9. 9.
    Shen Y, Luo Z, Yu Q, et al. Pharmacokinetics of dimemorfan phosphate tablets in healthy Chinese volunteers. Eur J Clin Pharmacol. 2017;73(6):709–15.CrossRefGoogle Scholar
  10. 10.
    Bioavailability and bioequivalence studies submitted in NDAs or INDs-general considerations. US FDA. 2014. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioavailability-and-bioequivalence-studies-submitted-ndas-or-inds-general-considerations. Accessed 16 Oct 2019.
  11. 11.
    Pain and Policy Studies Group. Opioid consumption data. https://ppsg-chart.medicine.wisc.edu/. Accessed 1 Jan 2019.
  12. 12.
    U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Abusedeterrent opioids—evaluation and labeling: guidance for industry. Silver Spring: US DoH; 2015.Google Scholar
  13. 13.
    OxyContin (oxycodone hydrochloride) extended-release tablets [package insert]. Stamford (CT): Purdue Pharma L.P.; 2016.Google Scholar
  14. 14.
    Poyhia R, Seppala T, Olkkola KT, et al. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol. 1992;33(6):617–21.CrossRefGoogle Scholar
  15. 15.
    Mandema JW, Kaiko RF, Oshlack B, Reder RF, Stanski DR. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. Br J Clin Pharmacol. 1996;42(6):747–56.CrossRefGoogle Scholar
  16. 16.
    Kokki M, Välitalo P, Rasanen I, Aaltomaa S, Ojanperä I, Eskelinen M, et al. Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy. Eur J Clin Pharmacol. 2012;68(10):1357–63.CrossRefGoogle Scholar
  17. 17.
    Kinnunen M, Piirainen P, Kokki H, et al. Updated clinical pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacokinet. 2019;58(6):705–25.CrossRefGoogle Scholar
  18. 18.
    Pöyhiä R, Vainio A, Kalso E. A review of oxycodone’s clinical pharmacokinetics and pharmacodynamics. J Pain Symptom Manag. 1993;8(2):63–7.CrossRefGoogle Scholar
  19. 19.
    Chen ZR, Irvine RJ, Somogyi AA, et al. Mu receptor binding of some commonly used opioids and their metabolites. Life Sci. 1991;48(22):2165–71.CrossRefGoogle Scholar
  20. 20.
    Alexander SPH, Mathie A, Peters JA. Guide to receptors and channels (GRAC), 4th edn. Br J Pharmacol. 2009;158(Suppl. 1):S1–25.Google Scholar
  21. 21.
    Kokki H, Kokki M. Central nervous system penetration of the opioid oxycodone. In: Preedy VR, editor. Neuropathology of drug addictions and substance misuse, vol. 3. 1st ed. New York: Academic; 2016 (ISBN 9780128006344).CrossRefGoogle Scholar
  22. 22.
    Bostrom E, Hammarlund-Udenaes M, Simonsson US. Blood–brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine. Anesthesiology. 2008;108(3):495–505.CrossRefGoogle Scholar
  23. 23.
    Bostrom E, Simonsson US, Hammarlund-Udenaes M. In vivo blood–brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics. Drug Metab Dispos. 2006;34(9):1624–31.CrossRefGoogle Scholar
  24. 24.
    Lemberg KK, Siiskonen AO, Kontinen VK, et al. Pharmacological characterization of noroxymorphone as a new opioid for spinal analgesia. Anesth Analg. 2008;106(2):463–70 (table of contents).CrossRefGoogle Scholar
  25. 25.
    Kokki M, Valitalo P, Kuusisto M, et al. Central nervous system penetration of oxycodone after intravenous and epidural administration. Br J Anaesth. 2014;112(1):133–40.CrossRefGoogle Scholar
  26. 26.
    Sadiq MW, Bostrom E, Keizer R, et al. Oxymorphone active uptake at the blood–brain barrier and population modeling of its pharmacokinetic–pharmacodynamic relationship. J Pharm Sci. 2013;102(9):3320–31.CrossRefGoogle Scholar
  27. 27.
    Vadivelu N, Chang D, Helander EM, et al. Ketorolac, oxymorphone, tapentadol, and tramadol: a comprehensive review. Anesthesiol Clin. 2017;35(2):e1–20.CrossRefGoogle Scholar
  28. 28.
    Klimas R, Witticke D, El Fallah S, et al. Contribution of oxycodone and its metabolites to the overall analgesic effect after oxycodone administration. Expert Opin Drug Metab Toxicol. 2013;9(5):517–28.CrossRefGoogle Scholar
  29. 29.
    Lalovic B, Kharasch E, Hoffer C, et al. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther. 2006;79(5):461–79.CrossRefGoogle Scholar
  30. 30.
    Samer CF, Daali Y, Wagner M, et al. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol. 2010;160(4):907–18.CrossRefGoogle Scholar
  31. 31.
    Samer CF, Daali Y, Wagner M, et al. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol. 2010;160(4):919–30.CrossRefGoogle Scholar
  32. 32.
    Zwisler ST, Enggaard TP, Noehr-Jensen L, et al. The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. Basic Clin Pharmacol Toxicol. 2009;104(4):335–44.CrossRefGoogle Scholar
  33. 33.
    Zwisler ST, Enggaard TP, Mikkelsen S, et al. Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia. Acta Anaesthesiol Scand. 2010;54(2):232–40.CrossRefGoogle Scholar
  34. 34.
    Stamer UM, Zhang L, Book M, et al. CYP2D6 genotype dependent oxycodone metabolism in postoperative patients. PLoS One. 2013;8(3):e60239.CrossRefGoogle Scholar
  35. 35.
    Gudin J, Levy-Cooperman N, Kopecky EA, et al. Comparing the effect of tampering on the oral pharmacokinetic profiles of two extended-release oxycodone formulations with abuse-deterrent properties. Pain Med. 2015;16(11):2142–51.CrossRefGoogle Scholar
  36. 36.
    Webster LR, Bath B, Medve RA, et al. Randomized, double-blind, placebo-controlled study of the abuse potential of different formulations of oral oxycodone. Pain Med. 2012;13(6):790–801.CrossRefGoogle Scholar
  37. 37.
    Franke RM, Morton T, Devarakonda K. Pooled post hoc analysis of population pharmacokinetics of oxycodone and acetaminophen following a single oral dose of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets. Drug Des Dev Ther. 2015;9:4587–97.Google Scholar
  38. 38.
    Liukas A, Kuusniemi K, Aantaa R, et al. Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups. Drugs Aging. 2011;28(1):41–50.CrossRefGoogle Scholar
  39. 39.
    Morton T, Franke R, Devarakonda K. Pooled post hoc analysis of population pharmacokinetics of oxycodone and acetaminophen following multiple oral doses of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets. Pain Pract. 2016;16(6):730–6.CrossRefGoogle Scholar
  40. 40.
    Andreassen TN, Klepstad P, Davies A, et al. Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients. Eur J Clin Pharmacol. 2011;67(5):493–506.CrossRefGoogle Scholar
  41. 41.
    Elder NM, Atayee RS, Best BM, et al. Observations of urinary oxycodone and metabolite distributions in pain patients. J Anal Toxicol. 2014;38(3):129–34.CrossRefGoogle Scholar
  42. 42.
    Davis MP. Pharmacokinetic and pharmacodynamic evaluation of oxycodone and naltrexone for the treatment of chronic lower back pain. Expert Opin Drug Metab Toxicol. 2016;12(7):823–31.CrossRefGoogle Scholar
  43. 43.
    Pergolizzi JV Jr, Taylor R Jr, LeQuang JA, et al. Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product. J Pain Res. 2018;11:301–11.CrossRefGoogle Scholar
  44. 44.
    Chindalore VL, Craven RA, Yu KP, et al. Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. J Pain. 2005;6(6):392–9.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Zhu Luo
    • 1
  • Jia Miao
    • 1
  • Shiqing Shu
    • 1
  • Ying Wang
    • 1
  • Xiaohong Zhu
    • 1
  • Chao Hu
    • 1
  • Yali Shen
    • 2
    Email author
  1. 1.GCP Center/Institute of Drug Clinical Trials, West China HospitalSichuan UniversityChengduPeople’s Republic of China
  2. 2.Department of Abdominal Oncology, Cancer Center, West China HospitalSichuan UniversityChengduPeople’s Republic of China

Personalised recommendations